Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $20.7300 (-1.71%) ($20.1900 - $21.1200) on Tue. Jul. 28, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.14% (three month average) | RSI | 30 | Latest Price | $20.7300(-1.71%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.4% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(58%) IWO(56%) ARKK(55%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.07% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-17%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.07% (StdDev 6.14%) | Hourly BBV | 0 () | Intraday Trend | -1.1% | | | |
|
Resistance Level | $21.96 | 5 Day Moving Average | $21.36(-2.95%) | 10 Day Moving Average | $21.93(-5.47%) | 20 Day Moving Average | $21.96(-5.6%) | To recent high | -14.2% | To recent low | 84.1% | Market Cap | $2.625b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |